SUBOXONE Drug Profile, 2023 PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download SUBOXONE Drug Profile, 2023 PDF full book. Access full book title SUBOXONE Drug Profile, 2023 by DrugPatentWatch. Download full books in PDF and EPUB format.
Author: DrugPatentWatch
Publisher: DrugPatentWatch.com
ISBN: 1934899445
Category : Medical
Languages : en
Pages : 366
Get Book Here
Book Description
SUBOXONE Drug Profile, 2023
This report focuses on SUBOXONE and covers the following critical aspects of this drug:
- United States patents
- Expired United States patents
- FDA Paragraph IV patent challenges
- District Court patent litigation
- Patent Trial and Appeal Board (PTAB) patent cases
- Clinical trials
- Drug prices
- Annual sales revenues
- Finished product suppliers
- Raw active pharmaceutical ingredient (API) sources
Author: DrugPatentWatch
Publisher: DrugPatentWatch.com
ISBN: 1934899445
Category : Medical
Languages : en
Pages : 366
Get Book Here
Book Description
SUBOXONE Drug Profile, 2023
This report focuses on SUBOXONE and covers the following critical aspects of this drug:
- United States patents
- Expired United States patents
- FDA Paragraph IV patent challenges
- District Court patent litigation
- Patent Trial and Appeal Board (PTAB) patent cases
- Clinical trials
- Drug prices
- Annual sales revenues
- Finished product suppliers
- Raw active pharmaceutical ingredient (API) sources
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309486483
Category : Medical
Languages : en
Pages : 175
Get Book Here
Book Description
The opioid crisis in the United States has come about because of excessive use of these drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use disorder (OUD). More than 2 million people in the United States are estimated to have OUD, which is caused by prolonged use of prescription opioids, heroin, or other illicit opioids. OUD is a life-threatening condition associated with a 20-fold greater risk of early death due to overdose, infectious diseases, trauma, and suicide. Mortality related to OUD continues to escalate as this public health crisis gathers momentum across the country, with opioid overdoses killing more than 47,000 people in 2017 in the United States. Efforts to date have made no real headway in stemming this crisis, in large part because tools that already existâ€"like evidence-based medicationsâ€"are not being deployed to maximum impact. To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, this report studies the evidence base on medication assisted treatment (MAT) for OUD. It examines available evidence on the range of parameters and circumstances in which MAT can be effectively delivered and identifies additional research needed.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309459575
Category : Medical
Languages : en
Pages : 483
Get Book Here
Book Description
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Author: Substance Abuse Mental Health Services Administration/SAMHSA (U.S.)
Publisher: Government Printing Office
ISBN: 0160943752
Category : Medical
Languages : en
Pages : 398
Get Book Here
Book Description
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat opioid use disorder (OUD)—methadone, naltrexone, and buprenorphine—and provides guidance for healthcare professionals and addiction treatment providers on appropriate prescribing practices for these medications and effective strategies for supporting the patients utilizing medication for the treatment of OUD. The goal of treatment for opioid addiction or OUD is remission of the disorder leading to lasting recovery. Recovery is a process of change through which individuals improve their health and wellness, live self-directed lives, and strive to reach their full potential. This TIP also educates patients, families, and the general public about how OUD medications work and the benefits they offer. Related products: Medication-Assisted Treatment of Opioid Use Disorder: Pocket Guide A Shared Burden: The Military and Civilian Consequences of Army Pain Management Since 2001 Click our Alcoholism, Smoking & Substance Abuse collection to find more resources on this topic.
Author: Eric C. Strain
Publisher:
ISBN:
Category : Medical
Languages : en
Pages : 360
Get Book Here
Book Description
Throughout the world, hundreds of thousands of people are addicted to opiates. The human, economic, and societal costs of this addiction are staggering: more than one-quarter of prison inmates are incarcerated for drug offenses and there has been a dramat.
Author: National Survey on Drug Use and Health (U.S.)
Publisher:
ISBN:
Category : Drug abuse
Languages : en
Pages : 320
Get Book Here
Book Description
Author: DrugPatentWatch
Publisher: DrugPatentWatch.com
ISBN: 1934899860
Category : Medical
Languages : en
Pages : 100
Get Book Here
Book Description
EDURANT Drug Profile, 2023
This report focuses on EDURANT and covers the following critical aspects of this drug:
- United States patents
- Expired United States patents
- District Court patent litigation
- European supplementary protection certificates (SPCs)
- Clinical trials
- Drug prices
- Finished product suppliers
- Raw active pharmaceutical ingredient (API) sources
Author: DrugPatentWatch
Publisher: DrugPatentWatch.com
ISBN: 1934899844
Category : Medical
Languages : en
Pages : 100
Get Book Here
Book Description
KAZANO Drug Profile, 2023
This report focuses on KAZANO and covers the following critical aspects of this drug:
- United States patents
- Expired United States patents
- FDA Paragraph IV patent challenges
- District Court patent litigation
- European supplementary protection certificates (SPCs)
- Clinical trials
- Drug prices
- Finished product suppliers
Author: U.S. Department of Health and Human Services
Publisher: Lulu.com
ISBN: 1794763538
Category : Reference
Languages : en
Pages : 84
Get Book Here
Book Description
The Federal Guidelines for Opioid Treatment Programs (Guidelines) describe the Substance Abuse and Mental Health Services Administration's (SAMHSA) expectation of how the federal opioid treatment standards found in Title 42 of the Code of Federal Regulations Part 8 (42 CFR � 8) are to be satisfied by opioid treatment programs (OTPs). Under these federal regulations, OTPs are required to have current valid accreditation status, SAMHSA certification, and Drug Enforcement Administration (DEA) registration before they are able to administer or dispense opioid drugs for the treatment of opioid addiction.
Author:
Publisher:
ISBN: 9780160943775
Category : Drug addicts
Languages : en
Pages : 322
Get Book Here
Book Description
